Meeting
2023 ASCO Annual Meeting
The ARETHA study: A phase 2 randomized control trial of eribulin with evexomostat (SDX-7320) or placebo for patients with metastatic triple-negative breast cancer (TNBC) and metabolic dysfunction.
Authors
Sherry Shen
Memorial Sloan Kettering Cancer Center, New York, NY
Sherry Shen , Verna Solomon , Dominiq Williams , Mark E. Robson , Larry Norton , Tiffany A. Traina , Neil M. Iyengar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT05570253
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS1131)
DOI
10.1200/JCO.2023.41.16_suppl.TPS1131
Abstract #
TPS1131
Poster Bd #
342a
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi
Poster
2024 ASCO Annual Meeting
Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.
First Author: Huiyan Luo
Poster
2023 ASCO Annual Meeting
A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.
First Author: Natalie Rainey
Poster
2023 ASCO Annual Meeting
ASCEND: A randomised, double-blinded, phase II study of gemcitabine and nab‐paclitaxel with CEND‐1/LSTA1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.
First Author: Andrew Peter Dean